- $38.25m
- -$2.47m
- $10.02m
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 4.96 | ||
| Price to Tang. Book | 97.74 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 4.78 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -96.95% | ||
| Return on Equity | -207.29% | ||
| Operating Margin | -501.16% | ||
Financial Summary
| Year End 31st Dec | Unit | 2019 | 2020 | 2021 | 2022 | 2023 | 2024E | 2025E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | 10 | 10.84 | 10.65 | 10.16 | 10.02 | 8.75 | 8.79 | -0.79% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Curis, Inc. is a biotechnology company. The Company is focused on the development of emavusertib (CA-4948), an orally available, small molecule inhibitor of Interleukin-1 receptor associated kinase (IRAK4). Emavusertib is undergoing testing in the Phase I/II TakeAim Lymphoma study in patients with relapsed/refractory primary central nervous system lymphoma (PCNSL) in combination with the BTK inhibitor ibrutinib, as a monotherapy in the Phase I/II TakeAim Leukemia study in patients with relapsed/refractory acute myeloid leukemia (AML) and relapsed/refractory high risk myelodysplastic syndrome (hrMDS). Its other clinical programs include Fimepinostat and CA-170. Fimepinostat is an oral, dual inhibitor of histone deacetylase (HDAC), and phosphotidyl-inositol 3 kinase (PI3K) enzymes. CA-170 is an oral small molecule drug candidate that is designed to selectively target V-domain Ig Suppressor of T-cell Activation (VISTA) and PDL1 immune checkpoint proteins.
Directors
- Martyn Greenacre NEC (79)
- James Dentzer PRE (54)
- William Steinkrauss CFO (35)
- Robert Martell OTH (58)
- John Hohneker DRC (61)
- Kenneth Kaitin IND (68)
- Lori Kunkel IND (63)
- Marc Rubin IND (66)
- Last Annual
- December 31st, 2023
- Last Interim
- March 31st, 2024
- Incorporated
- February 14th, 2000
- Public Since
- August 1st, 2000
- No. of Shareholders
- 128
- No. of Employees
- 48
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
NASDAQ Capital Market- Shares in Issue
- 5,894,085
- Address
- 128 Spring Street, 4 Maguire Road, LEXINGTON, 02421
- Web
- https://www.curis.com/
- Phone
- +1 6175036500
- Auditors
- PricewaterhouseCoopers LLP
Upcoming Events for CRIS
Q3 2024 Curis Inc Earnings Release
Similar to CRIS
180 Life Sciences
NASDAQ Capital Market
Abeona Therapeutics
NASDAQ Capital Market
ABVC Biopharma
NASDAQ Capital Market
Acesis Holdings
NASDAQ Capital Market
Achieve Life Sciences
NASDAQ Capital Market
FAQ
What is the Curis share price?
As of Today at 20:11 UTC, shares in Curis are trading at $7.96. This share price information is delayed by 15 minutes.
How has the Curis share price performed this year?
Shares in Curis last closed at $7.96 and the price had moved by -48.46% over the past 365 days. In terms of relative price strength the Curis share price has underperformed the S&P500 Index by -58.99% over the past year.
What are the analyst and broker recommendations for Curis?
The overall consensus recommendation for Curis is Buy. You can view the full broker recommendation list by unlocking its StockReport.
What is the Curis dividend yield?
Curis does not currently pay a dividend.
Does Curis pay a dividend?
Curis does not currently pay a dividend.
When does Curis next pay dividends?
Curis does not currently pay a dividend.
How do I buy Curis shares?
To buy shares in Curis you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Curis?
As of the previous close price of $7.96, shares in Curis had a market capitalisation of $46.92m.
Where are Curis shares listed?
Here are the trading details for Curis:
- Country of listing: United States
- Exchange: NAQ
- Ticker Symbol: CRIS
What kind of share is Curis?
Based on an overall assessment of its quality, value and momentum Curis is currently classified as a Sucker Stock. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Curis share price forecast for 2024?
The analyst consensus target price for shares in Curis is $22.50. That is 182.66% above the last closing price of $7.96.
Analysts covering Curis currently have a consensus Earnings Per Share (EPS) forecast of -$6.15 for the next financial year.
What is the trend in the Curis share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Curis. Over the past six months, its share price has underperformed the S&P500 Index by -49.53%.
As of the last closing price of $7.96, shares in Curis were trading -23.16% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Curis PE Ratio?
The Curis PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $7.96.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Curis?
Curis' management team is headed by:
- Martyn Greenacre - NEC
- James Dentzer - PRE
- William Steinkrauss - CFO
- Robert Martell - OTH
- John Hohneker - DRC
- Kenneth Kaitin - IND
- Lori Kunkel - IND
- Marc Rubin - IND